squamous histology, the overall incidence of pulmonary hemorrhage was 00% and the incidence of Grade ≥0 pulmonary hemorrhage was 0% for CYRAMZA with docetaxel compared to 00% overall incidence and 0% for Grade ≥0 pulmonary hemorrhage for placebo with docetaxel. Clinically relevant adverse reactions reported in ≥0% and <0% of CYRAMZA